Biocon Ltd. is in Pharmaceuticals & Drugs. It was incorporated in year 1978. The current market capitalisation stands Rs 27336 Cr. The company is listed on the Bombay Stock Exchange (BSE) with the BSE code as 532523. and also listed on National Stock Exchange (NSE) with NSE code as BIOCON.
Biocon Limited, a biopharmaceutical company, develops, manufactures, and sells biopharmaceuticals for diabetes, cancer, and autoimmune conditions. It operates through Small Molecule APIs and Generic Formulations, Biologics, Branded Formulations, and Research Services segments. The provides biosimilars comprising recombinant human insulin, insulin glargine, insulin lispro, insulin aspart, and monoclonal antibodies and other biologics; small molecules; and provides branded formulation products under the Insugen, Basalog, BIOMAb EGFR, CANMAb, and ALZUMAb brands. In addition, it is involved in the integrated discovery, development, and manufacturing services for novel molecules, including small molecules, large molecules, antibody-drug conjugates, and oligonucleotides. Further, the offers botanical products. It serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing.
Past performance is not indicative of future returns. Please consider your specific investment requirements, risk tolerance, investment goal, time frame, risk and reward balance and the cost associated with the investment before choosing a fund, or designing a portfolio that suits your needs.